MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Use with caution

Coversyl Arginine 10mg tablets (Sigma Pharmaceuticals Plc)

Explore other Perindopril arginine formulations Explore other Perindopril arginine 10mg tablets suppliers

Stability Notes

Protect from moisture. Maximum 8 days in a MCA.

Provenance

Compatibility recommendation derived from Coversyl Arginine 10mg tablets (Servier Laboratories Ltd).

Use with caution

Coversyl Arginine 2.5mg tablets (Servier Laboratories Ltd)

Explore other Perindopril arginine formulations Explore other Perindopril arginine 2.5mg tablets suppliers

Stability Notes

Protect from moisture. Maximum 8 days in a MCA.

Provenance

Compatibility recommendation derived from Coversyl Argininer 2.5mg tablets (Servier Laboratories Ltd).

Use with caution

Coversyl Arginine 5mg tablets (Lexon (UK) Ltd)

Explore other Perindopril arginine formulations Explore other Perindopril arginine 5mg tablets suppliers

Stability Notes

Protect from moisture. Maximum 8 days in a MCA.

Provenance

Compatibility recommendation derived from Coversyl Arginine 5mg tablets (Servier Laboratories Ltd).

Use with caution

Coversyl Arginine 5mg tablets (Servier Laboratories Ltd)

Explore other Perindopril arginine formulations Explore other Perindopril arginine 5mg tablets suppliers

Stability Notes

Protect from moisture. Maximum 8 days in a MCA.

Provenance

Compatibility recommendation derived from Coversyl Arginine 5mg tablets (Servier Laboratories Ltd).

Use with caution

Coversyl Arginine 5mg tablets (Sigma Pharmaceuticals Plc)

Explore other Perindopril arginine formulations Explore other Perindopril arginine 5mg tablets suppliers

Stability Notes

Protect from moisture. Maximum 8 days in a MCA.

Provenance

Compatibility recommendation derived from Coversyl Arginine 5mg tablets (Servier Laboratories Ltd).

Use with caution

Coversyl Arginine Plus 5mg/1.25mg tablets (Necessity Supplies Ltd)

Explore other Perindopril arginine + Indapamide formulations Explore other Perindopril arginine 5mg / Indapamide 1.25mg tablets suppliers

Stability Notes

Protect from moisture. Maximum 8 days in a MCA.

Provenance

Compatibility recommendation derived from Coversyl Arginine Plus 5mg/1.25mg tablets (Servier Laboratories Ltd).

Use with caution

Coversyl Arginine Plus 5mg/1.25mg tablets (Servier Laboratories Ltd)

Explore other Perindopril arginine + Indapamide formulations Explore other Perindopril arginine 5mg / Indapamide 1.25mg tablets suppliers

Stability Notes

Protect from moisture. Maximum 8 days in a MCA.

Provenance

Compatibility recommendation derived from Coversyl Arginine Plus 5mg/1.25mg tablets (Servier Laboratories Ltd).

Use with caution

Coversyl Arginine Plus 5mg/1.25mg tablets (Sigma Pharmaceuticals Plc)

Explore other Perindopril arginine + Indapamide formulations Explore other Perindopril arginine 5mg / Indapamide 1.25mg tablets suppliers

Stability Notes

Protect from moisture. Maximum 8 days in a MCA.

Provenance

Compatibility recommendation derived from Coversyl Arginine Plus 5mg/1.25mg tablets (Servier Laboratories Ltd).

Incompatible

Covonia Dry & Tickly Cough linctus (Thornton & Ross Ltd)

Explore other Glucose + Glycerol formulations Explore other Glycerol 1.36g/5ml / Glucose liquid 280mg/5ml oral solution suppliers

Stability Notes

There are no stability notes available for this medicine.

Use with caution

Cozaar 100mg tablets (CST Pharma Ltd)

Explore other Losartan formulations Explore other Losartan 100mg tablets suppliers

Stability Notes

Hygroscopic crystalline powder. Store in airtight containers and protect from light and moisture.

Provenance

This compatibility recommendation is derived from Cozaar 100mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Cozaar 100mg tablets (Lexon (UK) Ltd)

Explore other Losartan formulations Explore other Losartan 100mg tablets suppliers

Stability Notes

Hygroscopic crystalline powder. Store in airtight containers and protect from light and moisture.

Provenance

This compatibility recommendation is derived from Cozaar 100mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Cozaar 100mg tablets (Organon Pharma (UK) Ltd)

Explore other Losartan formulations Explore other Losartan 100mg tablets suppliers

Stability Notes

Hygroscopic crystalline powder. Store in airtight containers and protect from light and moisture.

Provenance

This compatibility recommendation is derived from Cozaar 100mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Cozaar 100mg tablets (Pilsco Ltd)

Explore other Losartan formulations Explore other Losartan 100mg tablets suppliers

Stability Notes

Hygroscopic crystalline powder. Store in airtight containers and protect from light and moisture.

Provenance

This compatibility recommendation is derived from Cozaar 100mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Cozaar 12.5mg tablets (CST Pharma Ltd)

Explore other Losartan formulations Explore other Losartan 12.5mg tablets suppliers

Stability Notes

Hygroscopic crystalline powder. Store in airtight containers and protect from light and moisture.

Provenance

This compatibility recommendation is derived from Cozaar 12.5mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Cozaar 12.5mg tablets (Organon Pharma (UK) Ltd)

Explore other Losartan formulations Explore other Losartan 12.5mg tablets suppliers

Stability Notes

Hygroscopic crystalline powder. Store in airtight containers and protect from light and moisture.

Provenance

This compatibility recommendation is derived from Cozaar 12.5mg tablets (Organon Pharma (UK) Ltd).

Print this list

Compatible

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.

Use with caution

Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.

Incompatible

Medicines under this category are not suitable for use inside MCAs.

No Stability Information

We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.